arqule inc
Kyowa Kirin Starts Phase III Trial Of ARQ197/Erlotinib In NSC Lung Cancer
Kyowa Hakko Kirin is starting a Phase III trial evaluating the combination of ARQ 197 (tivantinib) and erlotinib in Asia for patients with advanced or metastatic non-small cell lung cancer.



